{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-032821","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.710671+00:00","generated_at":"2026-05-26T06:03:34.262888+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inhibikase acquires CorHepta for $15M in stock; appoints Cabell as President and Adams as CSO","bullets":["Acquired CorHepta for $15M in stock: 4,979,101 shares issued (3,319,397 upfront, remainder contingent on milestone).","Chris Cabell appointed President & Head of R&D; former CorHepta CEO and ex-CMO of Arena Pharmaceuticals.","Vincent Aurentz appointed to Board; former EVP/Chief Business Officer at Arena (acquired by Pfizer for $6.7B).","John Adams appointed Chief Scientific Officer; co-founder of CorHepta, former Head of Research at Arena.","Dr. Cabell employment: $500K base, 45% bonus, 2.81M stock options vesting over 4 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-032821","json":"https://secwatch.observer/filing/0001193125-25-032821.json","markdown":"https://secwatch.observer/filing/0001193125-25-032821.md","text":"https://secwatch.observer/filing/0001193125-25-032821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/0001193125-25-032821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/d889659d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:03:34.262888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02b1fd271e","claim":"Vincent Aurentz was appointed as Class I director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"The Board also expanded its size from seven to eight directors and appointed Vincent Aurentz to serve as a Class I director of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/0001193125-25-032821-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"},{"claim_id":"c44ccd48d1","claim":"Chris Cabell was appointed as President and Head of Research and Development at Inhibikase Therapeutics, Inc..","evidence_excerpt":"the Board appointed Chris Cabell as President and Head of Research and Development of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/0001193125-25-032821-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Head of Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}